New hope for liver cancer: experimental combo aims to extend life
NCT ID NCT07226063
First seen Nov 11, 2025 · Last updated May 14, 2026 · Updated 21 times
Summary
This study tests whether adding the experimental drug zanzalintinib to the approved drug durvalumab can help people with advanced liver cancer live longer. It is for patients whose cancer was stable or improved after initial treatment with tremelimumab and durvalumab. About 16 adults will take both drugs as maintenance therapy. The goal is to see if this combination delays cancer growth.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center
Cleveland, Ohio, 44106, United States
Contact
Contact
Conditions
Explore the condition pages connected to this study.